Press Releases
2010
2009
- September 28 - Abbott to Acquire Solvay Pharmaceuticals Business
- August 24 - Health Canada Approves Abbott’s XIENCE V® Drug Eluting Stent
- April 27 - Interim Results of Abbott’s PROGRESS Study Show Rapid Viral Decline in Dual-Therapy Regimen of Kaletra (lopinavir/ritonavir) and Raltegravir
- April 15 - Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009
- February 20 - Abbott Announces 11 Percent Increase in Quarterly Dividend
- February 18 - Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
- January 21 - Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings
- January 15 - Abbott Nutrition Statement on Melamine and Cyanuric Acid
2008
- December 12 - Abbott Declares 340th Consecutive Quarterly Dividend
- September 26 - Standby Statement for Medical Nutrition products
- September 18 - Abbott Nutrition Statement on Infant Formula Contamination in China
- August 7 - Abbott Study Shows Investigational Heat-Stable Norvir® Tablet Provides Similar Drug Levels to Current Norvir Capsule
- August 7 - Abbott Virology is proud to sponsor The Electronic Wake, a unique summer event that will leave no one untouched
- August 5 - Abbott’s Kaletra® Tablet : Similar Clinical Results Across Race and Gender Lines
- July 29 - Abbott Prepares to Submit Heat-Stable Norvir® Tablet for Registration by End of Year
- July 16 - Abbott Reports Stronger-than-Expected Sales and Earnings Growth in Second Quarter and Raises Full-Year Outlook
- June 17 - Abbott Nutrition Introduces New Web-Based Lifestyle Program for People with Diabetes
- May 21 - Abbott Presents Long-term Data from Extension Study Showing Adult Crohn’s Patients Treated with HUMIRA® (Adalimumab) Maintained Remission
- Jan. 24 - HUMIRA® is Now Approved in Canada for the Treatment of Moderate-to-Severe Plaque Psoriasis
- Jan. 21 - Health Canada approves HUMIRA® (adalimumab) for treatment of Crohn's disease
- Jan. 10 - Abbott Named One the 50 Best Employers in Canada for Third Consecutive Year
2007
- Dec. 12 - Synagis® May Reduce Subsequent Recurrent Wheezing in Preterm Infants
- Oct. 18 - Abbott Scientists Create One Molecule With Two Antibody Functions
- Sept. 27 - Abbott's HUMIRA® (adalimumab) Honored with Prestigious Galen Prize for Innovation in Patient Care
- Sept. 17 - Abbott Submits Canada, E.U. and U.S. Regulatory Filings for New Lower-Strength Kaletra® and Aluvia® (lopinavir/ritonavir) Tablet Suitable for Pediatric Use
- July 17 - Abbott submits E.U. and U.S. Regulatory Filings for New Lower-Strength Kaletra®
- May 14 - PUBLIC COMMUNICATION: Voluntary Recall of Depakene® 500-mg
- May 11 - HEALTHCARE PROFESSIONALS COMMUNICATION: Voluntary Recall of Depakene® 500-mg
- April 30 - Abbott Seeks Health Canada Approval of Humira® for Psoriasis
- March 23 - Abbott launches new antibiotic for AECB
- Feb. 13 - Abbott Recognized as One of Canada's "50 Best Employers" by Hewitt Associates
- Jan. 18 - Abbott Diagnostics To Be Acquired By General Electric
2006
- Nov. 7 - Humira approved in Canada for treatment of AS
- Oct. 9 - Abbott in The Montreal Gazette, October 9, 2006
- Sept. 12 - Abbott´s New Tablet Formulation of Kaletra Approved in Canada
- Sept. 12 - Now available : KALETRA Tablets!
2005
- Oct. 19 - New Humira travel kit
- Oct. 17 - Humira now on eight government drug plans
